These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 3083211)
1. Clinical trials of sorbinil on nerve function. Pfeifer MA Metabolism; 1986 Apr; 35(4 Suppl 1):78-82. PubMed ID: 3083211 [TBL] [Abstract][Full Text] [Related]
2. Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity. Pfeifer MA Am J Med; 1985 Nov; 79(5A):18-23. PubMed ID: 3934964 [TBL] [Abstract][Full Text] [Related]
8. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776 [TBL] [Abstract][Full Text] [Related]
9. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)]. Christensen JE; Larsen AB; Gregersen G Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975 [No Abstract] [Full Text] [Related]
10. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Tomlinson DR; Moriarty RJ; Mayer JH Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576 [TBL] [Abstract][Full Text] [Related]
11. Improvement in peripheral nerve function after one year of Sorbinil. Gieron MA; Malone JI; Lowitt S; Korthals JK Neuroreport; 1991 Jun; 2(6):348-50. PubMed ID: 1655107 [TBL] [Abstract][Full Text] [Related]
12. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187 [TBL] [Abstract][Full Text] [Related]
13. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study. Christensen JE; Varnek L; Gregersen G Acta Neurol Scand; 1985 Feb; 71(2):164-7. PubMed ID: 3920861 [TBL] [Abstract][Full Text] [Related]
14. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Fagius J; Brattberg A; Jameson S; Berne C Diabetologia; 1985 Jun; 28(6):323-9. PubMed ID: 3930330 [TBL] [Abstract][Full Text] [Related]
15. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of aldose reductase in human diabetic neuropathy. Jaspan J Drugs; 1986; 32 Suppl 2():23-9. PubMed ID: 2431859 [TBL] [Abstract][Full Text] [Related]
18. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Jaspan J; Maselli R; Herold K; Bartkus C Lancet; 1983 Oct; 2(8353):758-62. PubMed ID: 6137601 [TBL] [Abstract][Full Text] [Related]
19. The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation. van Gerven JM; Tjon-A-Tsien AM Drugs Aging; 1995 Jan; 6(1):9-28. PubMed ID: 7696781 [TBL] [Abstract][Full Text] [Related]
20. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function. Martyn CN; Reid W; Young RJ; Ewing DJ; Clarke BF Diabetes; 1987 Sep; 36(9):987-90. PubMed ID: 3111914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]